ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 020,11
0,34%
Dow Jones
38 686,32
1,51%
DAX
18 621,31
0,75%
Brent Oil
81,14
0,41%
Bitcoin
69 247,11
2,21%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Arbutus Biopharma Corporation (ABUS)

  7. Arbutus Biopharma Corporation (ABUS) Actualités

ABUS

Arbutus Biopharma (ABUS)

Arbutus Biopharma Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ABUS
DateHeureSourceTitreSymboleSociété
29/05/202413h30GlobeNewswire Inc.Arbutus to Participate in Jefferies Global Healthcare ConferenceNASDAQ:ABUSArbutus Biopharma Corporation
28/05/202422h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
24/05/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
22/05/202408h00GlobeNewswire Inc.Arbutus to Present Imdusiran Data at EASL Congress 2024NASDAQ:ABUSArbutus Biopharma Corporation
17/05/202415h03Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ABUSArbutus Biopharma Corporation
17/05/202415h00Business WireWhitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize ValueNASDAQ:ABUSArbutus Biopharma Corporation
09/05/202414h00Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:ABUSArbutus Biopharma Corporation
07/05/202413h30GlobeNewswire Inc.Arbutus to Participate in Two Upcoming Investor ConferencesNASDAQ:ABUSArbutus Biopharma Corporation
02/05/202413h30GlobeNewswire Inc.Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
02/05/202413h25GlobeNewswire Inc.Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024NASDAQ:ABUSArbutus Biopharma Corporation
18/04/202413h30GlobeNewswire Inc.Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
04/04/202414h30GlobeNewswire Inc.Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against ModernaNASDAQ:ABUSArbutus Biopharma Corporation
05/03/202422h48Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ABUSArbutus Biopharma Corporation
29/02/202413h30GlobeNewswire Inc.Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
15/02/202413h30GlobeNewswire Inc.Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
14/02/202422h38Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABUSArbutus Biopharma Corporation
08/01/202413h30GlobeNewswire Inc.Arbutus Announces 2024 Corporate Objectives and Provides Financial UpdateNASDAQ:ABUSArbutus Biopharma Corporation
21/11/202314h00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ABUSArbutus Biopharma Corporation
08/11/202313h30GlobeNewswire Inc.Arbutus to Present at Jefferies London Healthcare ConferenceNASDAQ:ABUSArbutus Biopharma Corporation
07/11/202322h18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABUSArbutus Biopharma Corporation
07/11/202313h30GlobeNewswire Inc.Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
07/11/202313h15GlobeNewswire Inc.Arbutus Announces CEO, William Collier, to Retire December 31, 2023NASDAQ:ABUSArbutus Biopharma Corporation
24/10/202313h30GlobeNewswire Inc.Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
18/10/202313h30GlobeNewswire Inc.Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual ConferenceNASDAQ:ABUSArbutus Biopharma Corporation
11/10/202314h05GlobeNewswire Inc.Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023NASDAQ:ABUSArbutus Biopharma Corporation
11/09/202322h15GlobeNewswire Inc.Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway ExtendedNASDAQ:ABUSArbutus Biopharma Corporation
03/08/202322h18Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ABUSArbutus Biopharma Corporation
03/08/202313h30GlobeNewswire Inc.Arbutus Reports Second Quarter 2023 Financial Results and Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
20/07/202313h30GlobeNewswire Inc.Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
13/07/202322h11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
 Showing the most relevant articles for your search:NASDAQ:ABUS

Dernières Valeurs Consultées

TSX
HUBL.U
Harvest US Bank Leaders ...
TG
A3KQET
Oriflame Investment
COIN
MP3USD
mp3
TG
A19D53
Johnson and Johnson
BOV
USIM5
USIMINAS PNA
USOTC
MEDVF
Medivolve (PK)
EU
SDGPS
Societe du Grand Paris D...
TG
A3LWD6
Amadeus IT
EU
U535S
U535S
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés